Northern Trust
EIGR

Northern Trust’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Northern Trust’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,744
Closed -$25.2K – 4502
2023
Q4 		$25.2K Hold
3,744
– – ﹤0.01% 4335
2023
Q3 		$34.3K Sell
3,744
-667
-15% -$13.4K ﹤0.01% 4247
2023
Q2 		$93.2K Sell
4,411
-8,968
-67% -$276K ﹤0.01% 4055
2023
Q1 		$360K Sell
13,379
-246
-2% -$11.4K ﹤0.01% 3589
2022
Q4 		$482K Buy
13,625
+220
+2% +$26.4K ﹤0.01% 3519
2022
Q3 		$3.03M Buy
13,405
+302
+2% +$74.2K ﹤0.01% 2780
2022
Q2 		$2.48M Buy
13,103
+2,327
+22% +$469K ﹤0.01% 2933
2022
Q1 		$2.68M Sell
10,776
-398
-4% -$62.9K ﹤0.01% 2947
2021
Q4 		$1.74M Sell
11,174
-228
-2% -$44.1K ﹤0.01% 3289
2021
Q3 		$2.29M Sell
11,402
-436
-4% -$104K ﹤0.01% 3219
2021
Q2 		$3.02M Sell
11,838
-614
-5% -$153K ﹤0.01% 3150
2021
Q1 		$3.31M Sell
12,452
-1,929
-13% -$608K ﹤0.01% 2996
2020
Q4 		$5.3M Buy
14,381
+588
+4% +$169K ﹤0.01% 2656
2020
Q3 		$3.37M Buy
13,793
+872
+7% +$271K ﹤0.01% 2767
2020
Q2 		$3.72M Buy
12,921
+2,190
+20% +$646K ﹤0.01% 2695
2020
Q1 		$2.19M Buy
10,731
+616
+6% +$196K ﹤0.01% 2805
2019
Q4 		$4.52M Buy
10,115
+167
+2% +$59.3K ﹤0.01% 2644
2019
Q3 		$3.06M Buy
9,948
+6,986
+236% +$2.27M ﹤0.01% 2847
2019
Q2 		$942K Buy
2,962
+1,083
+58% +$375K ﹤0.01% 3378
2019
Q1 		$788K Sell
1,879
-146
-7% -$58.6K ﹤0.01% 3432
2018
Q4 		$617K Buy
2,025
+447
+28% +$144K ﹤0.01% 3507
2018
Q3 		$568K Buy
1,578
+226
+17% +$77.3K ﹤0.01% 3607
2018
Q2 		$495K Buy
1,352
+373
+38% +$133K ﹤0.01% 3600
2018
Q1 		$289K Buy
979
+616
+170% +$182K ﹤0.01% 3719
2017
Q4 		$152K Buy
+363
New +$130K ﹤0.01% 3891
2017
Q2 		– Sell
-1,374
Closed -$472K – 4308
2017
Q1 		$472K Buy
1,374
+107
+8% +$36.9K ﹤0.01% 3557
2016
Q4 		$443K Buy
1,267
+27
+2% +$9.89K ﹤0.01% 3558
2016
Q3 		$498K Buy
1,240
+116
+10% +$59.2K ﹤0.01% 3514
2016
Q2 		$668K Buy
+1,124
New +$683K ﹤0.01% 3452
2016
Q1 		– Sell
-75
Closed -$49K – 4296
2015
Q4 		$49K Hold
75
– – ﹤0.01% 4048
2015
Q3 		$35K Buy
75
+17
+29% +$9.02K ﹤0.01% 4132
2015
Q2 		$33K Buy
58
+19
+49% +$52.6K ﹤0.01% 4110
2015
Q1 		$332K Buy
39
+2
+5% +$17.5K ﹤0.01% 3728
2014
Q4 		$329K Buy
37
+3
+9% +$17.4K ﹤0.01% 3680
2014
Q3 		$162K Sell
34
-98
-74% -$518K ﹤0.01% 3898
2014
Q2 		$952K Buy
132
+78
+144% +$390K ﹤0.01% 3413
2014
Q1 		$290K Buy
+54
New +$255K ﹤0.01% 3689

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
AWP
Accretive Wealth Partners Parsippany, New Jersey $356M AUM 14.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Northern Trust's EIGR Position: Q1 2024 in Review

Northern Trust sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2024, closing a stake of 3,744 shares — an estimated $25.2K sold.

Northern Trust first reported a position in EIGR in Q1 2014 and held it in 37 quarters. The position peaked at $5.3M in Q4 2020. 24 funds tracked by Wall St. Rank hold EIGR as of Q1 2024.

  • Northern Trust reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
  • Northern Trust sold 3,744 Eiger BioPharmaceuticals, Inc. shares in Q1 2024, an estimated $25.2K.
  • Northern Trust first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 37 quarters.
  • Northern Trust's Eiger BioPharmaceuticals, Inc. position peaked at $5.3M in Q4 2020.
  • 24 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2024.

Based on Northern Trust's 13F filing for Q1 2024, filed 14 May 2024.